​

Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNA Stock Forecast

Avidity Biosciences (RNA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $59.00, with a high of $59.00 and a low of $59.00. This represents a 84.84% increase from the last price of $31.92.

$5 $16 $27 $38 $49 $60 High: $59 Avg: $59 Low: $59 Last Closed Price: $31.92

RNA Stock Rating

Avidity Biosciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 1 Strong Buy (12.50%), 7 Buy (87.50%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 7 1 Strong Sell Sell Hold Buy Strong Buy

RNA Forecast vs Benchmarks

TypeNameUpside
StockAvidity Biosciences84.84%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$54.50
Last Closing Price$31.92$31.92$31.92
Upside/Downside--70.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2547---11
Dec, 2448---12
Nov, 2448---12
Oct, 2438---11
Sep, 2438---11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024Corinne JohnsonGoldman Sachs$59.00$43.5035.63%84.84%
Jun 12, 2024Yanan ZhuWells Fargo$50.00$28.9272.89%56.64%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 21, 2024NeedhamBuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 03, 2024Goldman SachsBuyBuyhold
Sep 24, 2024Goldman SachsBuyinitialise
Sep 16, 2024Evercore PartnersUnderperformUnderperformhold
Aug 28, 2024BarclaysOverweightinitialise
Aug 12, 2024NeedhamBuyBuyhold
Jun 25, 2024Cowen & Co.BuyBuyhold
Jun 13, 2024Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.83$-3.24$-2.91-----
Avg Forecast$-1.80$-2.73$-3.36$-2.65$-2.87$-3.30$-3.57$-1.85$1.53
High Forecast$-2.20$-3.34$-4.83$-2.98$-2.99$-4.49$-4.63$-3.20$0.81
Low Forecast$-1.39$-2.11$-2.07$-1.86$-2.70$-2.45$-2.17$-0.03$2.24
Surprise %12.78%3.66%-3.57%9.81%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.79M$9.33M$9.22M$9.56M-----
Avg Forecast$5.47M$9.51M$8.32M$19.58M$9.74M$7.11M$21.89M$307.80M$861.96M
High Forecast$4.53M$7.87M$5.87M$5.92M$7.46M$4.54M$20.90M$196.62M$550.63M
Low Forecast$6.42M$11.16M$11.13M$46.62M$12.09M$9.67M$22.88M$418.75M$1.17B
Surprise %23.96%-1.98%10.84%-51.17%-----

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.98M$-117.37M$-169.08M$-212.22M-----
Avg Forecast$-131.18M$-199.05M$-245.03M$-212.22M$-207.69M$-253.46M$-248.49M$-118.09M$111.56M
High Forecast$-160.58M$-243.66M$-352.61M$-217.24M$-218.20M$-327.84M$-338.34M$-233.67M$59.18M
Low Forecast$-101.73M$-154.36M$-151.35M$-136.14M$-197.17M$-179.08M$-158.64M$-2.51M$163.85M
Surprise %-66.47%-41.03%-31.00%------

RNA Forecast FAQ

Is Avidity Biosciences stock a buy?

Avidity Biosciences stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Avidity Biosciences is a favorable investment for most analysts.

What is Avidity Biosciences's price target?

Avidity Biosciences's price target, set by 8 Wall Street analysts, averages $59 over the next 12 months. The price target range spans from $59 at the low end to $59 at the high end, suggesting a potential 84.84% change from the previous close price of $31.92.

How does Avidity Biosciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

Avidity Biosciences stock forecast shows a 84.84% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Avidity Biosciences over the past three months?

  • January 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Avidity Biosciences’s EPS forecast?

Avidity Biosciences's average annual EPS forecast for its fiscal year ending in December is -2.87 for 2024, a -1.37% decrease from the reported $-2.91 in 2023. The prediction for 2025 is $-3.3, $-3.57 for 2026, $-1.85 for 2027, and $1.53 for 2028.

What is Avidity Biosciences’s revenue forecast?

Avidity Biosciences's average annual revenue forecast for its fiscal year ending in December is $9.74M for 2024, a 1.89% increase from the reported $9.56M in 2023. The forecast for 2025 is $7.11M, $21.89M for 2026, $307.8M for 2027, and $861.96M for 2028.

What is Avidity Biosciences’s net income forecast?

For its fiscal year ending in December, Avidity Biosciences's average annual net income forecast is $-208M for 2024, reflecting a -2.14% decrease from the reported $-212M in 2023. The projection for 2025 is $-253M, $-248M for 2026, $-118M for 2027, and $111.56M for 2028.